Skip to main
NKTR

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

Nektar Therapeutics (NKTR) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Nektar Therapeutics is positioned well in the field of immunotherapy, with several promising treatments in development for autoimmune diseases and cancer. The company has a diverse pipeline, including rezpegaldesleukin, a potential treatment for alopecia areata, which presents a significant whitespace against competitors and has the potential for significant revenue. Additionally, the company has a strong financial position, with a cash balance of $33 million and multiple ongoing studies, indicating a positive outlook for the company's future growth and success.

Bears say

Nektar Therapeutics is facing significant risks to its stock outlook due to concerns about potential clinical and regulatory failures for its key drug candidate, rezpegaldesleukin, which is being developed for the treatment of autoimmune diseases and cancer. Additionally, there are potential commercial challenges and logistical issues that could impact the company's ability to generate sales and distribute its drugs in a timely manner. It will be important for the company to successfully navigate these challenges in order to meet its financial projections and maintain investor confidence.

Nektar Therapeutics (NKTR) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nektar Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nektar Therapeutics (NKTR) Forecast

Analysts have given Nektar Therapeutics (NKTR) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Nektar Therapeutics (NKTR) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $151, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $151, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nektar Therapeutics (NKTR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.